PURE Bioscience, Inc.
PURE
$0.08
$0.000.60%
OTC PK
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 444.00K | 708.00K | 764.00K | 491.00K | 391.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 444.00K | 708.00K | 764.00K | 491.00K | 391.00K |
| Cost of Revenue | 206.00K | 258.00K | 296.00K | 208.00K | 164.00K |
| Gross Profit | 238.00K | 450.00K | 468.00K | 283.00K | 227.00K |
| SG&A Expenses | 847.00K | 743.00K | 731.00K | 776.00K | 871.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.13M | 1.09M | 1.10M | 1.08M | 1.12M |
| Operating Income | -683.00K | -379.00K | -336.00K | -584.00K | -725.00K |
| Income Before Tax | -785.00K | -464.00K | -332.00K | -580.00K | -798.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -785.00K | -464.00K | -332.00K | -580.00K | -798.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -785.00K | -464.00K | -332.00K | -580.00K | -798.00K |
| EBIT | -683.00K | -379.00K | -336.00K | -584.00K | -725.00K |
| EBITDA | -682.00K | -378.00K | -336.00K | -583.00K | -724.50K |
| EPS Basic | -0.01 | 0.00 | 0.00 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | 0.00 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 111.89M | 111.89M | 111.88M | 111.86M | 111.86M |
| Average Diluted Shares Outstanding | 111.89M | 111.89M | 111.88M | 111.86M | 111.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |